AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), DEEPSEEK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History & Clinical Presentation (Timestamp: 4 Weeks Prior to Admission)
A 22-year-old female student residing in the Delhi NCR region (with no prior chronic medical history) presents to a tertiary care hospital with subacute progressive dyspnea on exertion, atypical retrosternal chest tightness, a non-productive cough, and generalized fatigue of 4 weeks duration. She denies fever, weight loss, hemoptysis, or joint pains.
Urinalysis at an outpatient clinic noted persistent microscopic hematuria (15-20 RBCs/hpf without overt gross hematuria). Plasma D-dimer was elevated.
Past Medical & Surgical History: None.
Social & Exposure History: Non-smoker, no alcohol or substance use. No history of unpasteurized milk ingestion, pet contact, or tuberculosis exposure. Family history: Unremarkable for autoimmune or renal disease.

Resident:

Hello, Chief Resident here.

Key Findings:
* 22-year-old female with 4-week subacute dyspnea, retrosternal chest tightness, dry cough, and fatigue.
* Microscopic hematuria (15-20 RBCs/hpf) and elevated D-dimer.

Differential Diagnoses:
1. Systemic Lupus Erythematosus (SLE) / Antiphospholipid Syndrome (APS) with PE/Nephritis: 40% – Classic demographic; accounts for multisystem pulmonary-renal features and hypercoagulability.
2. ANCA-Associated Vasculitis (Pulmonary-Renal Syndrome): 25% – Subacute respiratory symptoms paired with persistent glomerular hematuria.
3. Acute Pulmonary Embolism (PE) secondary to Inherited/Acquired Thrombophilia: 20% – Explains dyspnea, retrosternal tightness, and elevated D-dimer; hematuria may be concurrent or related to renal infarction/thrombosis.
4. IgA Nephropathy / Post-Infectious Glomerulonephritis with Atypical Pneumonia: 15% – Coincident renal and respiratory presentation.

Recommended Next Tests:
1. CT Pulmonary Angiography (CTPA): Evaluate for acute/subacute PE.
2. Autoimmune Serologies: ANA, anti-dsDNA, ANCAs, C3/C4, and antiphospholipid antibodies (aPL).
3. Urine Protein-to-Creatinine Ratio (UPCR) & RBC Morphology/Casts Analysis.
4. Transthoracic Echocardiogram (TTE): Assess for pulmonary hypertension, right heart strain, or pericardial effusion.
5. HRCT Chest: Evaluate for parenchymal or interstitial lung disease if CTPA is negative for embolism.

Attending:

Hello Attending Consultant here

Top 3 Differentials:
1. Systemic Lupus Erythematosus with lupus nephritis and possible APLS-related PE/pneumonitis
2. ANCA-associated vasculitis (e.g., GPA) — pulmonary-renal syndrome
3. Anti-GBM disease (Goodpasture’s) — albeit rarer, classic alveolar hemorrhage and glomerulonephritis

Critique & Suggested Refinements:
Your workup is well-structured but omits critical early steps. The D-dimer elevation is nonspecific; direct pursuit of PE must not delay evaluation for a pulmonary-renal syndrome.

  1. Immediate serum creatinine/eGFR — mandatory for classification and urgency.
  2. Add anti-GBM antibody to serologies; a negative ANCA does not exclude Goodpasture’s.
  3. Urine microscopy for dysmorphic RBCs/casts — you requested UPCR and morphology but emphasize acanthocytes and red cell casts to confirm glomerular source.
  4. CT chest should be a CTPA with high-resolution cuts — combine in one study to assess emboli, nodules, cavities, or ground-glass (hemorrhage).
  5. Empiric pulse steroids (e.g., methylprednisolone 500 mg IV) while awaiting serologies if rapidly progressive; do not delay for biopsy if life-threatening.
  6. Renal biopsy planning — if acute kidney injury or nephritic sediment, biopsying early is diagnostic for SLE, vasculitis, or anti-GBM.
  7. Avoid HRCT-only sequence — a negative CTPA with persistent hypoxemia mandates bronchoscopy with BAL for alveolar hemorrhage.

Expert:

Hello, Expert Clinician here.

Best Unifying Diagnosis: SLE with lupus nephritis and pulmonary involvement — antiphospholipid-mediated pulmonary embolism or lupus pneumonitis. A young woman with pulmonary symptoms, glomerular hematuria, and elevated D-dimer demands a systemic explanation.

Top Differentials:
- ANCA-associated vasculitis (GPA/MPA): Fits a pulmonary-renal syndrome; less likely without hemoptysis or upper airway disease, but serologies are mandatory.
- Anti-GBM disease: Classic pulmonary-renal syndrome, but absent hemoptysis argues against it; must still be excluded.
- Primary PE with incidental hematuria: Explains dyspnea, chest tightness, and D-dimer, but fails to unify the hematuria — anchoring here is the principal pitfall.

Key Pivot: The microscopic hematuria. It converts "possible PE" into a pulmonary-renal/autoimmune syndrome. D-dimer is nonspecific and may reflect systemic inflammation rather than clot.

Most Important Next Move: Simultaneous, not sequential — CTPA (PE is immediately

Round 2

User:

Stage 2: Physical Exam, Baseline Labs & CT Chest (Timestamp: Admission / Day 1)
Physical Exam: T 36.8°C, HR 88 bpm, BP 118/74 mmHg, RR 18/min, SpO2 98% on room air. Well-nourished, non-distressed. Head & Neck: Mucous membranes moist, no nasal septal perforation, saddle nose deformity, or oral ulcers on preliminary examination. Chest: Clear breath sounds bilaterally. Cardiac: Normal S1/S2, no pericardial rub. Abdomen: Soft, non-tender. Extremities: No pedal edema, no purpuric skin rash or cutaneous vasculitis.
Initial Laboratory Evaluation:
- Hemogram: Hemoglobin 12.1 g/dL, Total Leukocyte Count 7,200/µL (normal differential), Platelets 260,000/µL.
- Inflammatory Markers: ESR 52 mm/1st hr, CRP 38 mg/L. Renal & Liver functions normal (Serum Creatinine 0.7 mg/dL).
- Urinalysis: Microscopic hematuria (15-20 dysmorphic RBCs/hpf, 1+ proteinuria, no RBC casts).
Initial Imaging:
- CT Chest Angiography: Demonstrated a large subcarinal mediastinal mass (subcarinal lymphadenopathy) causing extrinsic compression and severe stenosis of the right pulmonary artery (RPA) trunk and main pulmonary artery bifurcation, associated with multiple mediastinal/hilar lymph nodes and a moderate pericardial effusion.

Resident:

Hello, Chief Resident here.

Key Findings:
* Subcarinal mediastinal lymphadenopathy causing severe extrinsic stenosis of the right pulmonary artery.
* Moderate pericardial effusion and elevated inflammatory markers (ESR 52, CRP 38).
* Glomerular microscopic hematuria (dysmorphic RBCs) with normal serum creatinine.

Differential Diagnoses:
1. Tuberculosis (Mediastinal Tubercular Lymphadenitis): 35% – High-prevalence region (Delhi NCR); subacute necrotic mediastinal adenopathy can cause vascular compression and reactive immune-complex glomerulonephritis.
2. Lymphoma (Hodgkin’s / Non-Hodgkin’s): 30% – Primary cause of bulky subcarinal masses in young adults; hematuria may be paraneoplastic/incidental.
3. Sarcoidosis: 20% – Symmetrical/bulky lymphadenopathy with potential renal and pericardial involvement.
4. Systemic Autoimmune Disease (SLE / GPA): 15% – Unifies pericardial effusion and glomerular hematuria, though severe vascular extrinsic compression is atypical.

Recommended Next Tests:
1. EBUS-guided Transbronchial Needle Aspiration (EBUS-TBNA): Subcarinal mass biopsy for histopathology, cytology/flow cytometry, GeneXpert (MTB/RIF), and AFB/fungal cultures.
2. Autoimmune Serologies: ANA, anti-dsDNA, ANCA, and complement levels (C3/C4).
3. Interferon-Gamma Release Assay (IGRA / QuantiFERON-TB).
4. Urine Protein-to-Creatinine Ratio (UPCR).
5. Repeat Echocardiogram: Evaluate right ventricular hemodynamics, PA flow velocities, and pericardial effusion stability.

Attending:

Hello Attending Consultant here

Top 3 Differentials (Refined by the Subcarinal Mass):
1. Tuberculous mediastinal lymphadenitis with immune-complex glomerulonephritis (e.g., IgA-dominant)
2. Sarcoidosis — granulomatous mediastinal/hilar adenopathy, pericardial effusion, and possible interstitial nephritis or GN
3. Lymphoma (Hodgkin’s) with paraneoplastic glomerulonephritis

Critique and Augmentation of the Chief Resident’s Plan:

  1. EBUS-TBNA is critical, but expand sampling: Ensure core biopsy for histology

Expert:

Attending:
...and cytology, flow cytometry, GeneXpert MTB/RIF, AFB smear/culture, and fungal studies from the same pass. A single inadequate aspirate is the most common cause of diagnostic delay here.

  1. Geography matters: In Delhi NCR, necrotic subcarinal nodes with vascular compression are TB until proven otherwise. However, do not start empiric ATT or steroids before tissue — steroids can transiently shrink lymphoma and disseminate TB, destroying the diagnostic window.

  2. Pericardial effusion needs characterization, not just observation: Repeat echo within 24 hours for tamponade physiology. If significant, pericardiocentesis with fluid ADA, GeneXpert, cytology, and cell count is both diagnostic and therapeutic — TB pericarditis would unify the picture.

  3. Reframe the hematuria: Dysmorphic RBCs confirm a glomerular source, but with normal creatinine, no casts, and only 1+ protein, this is likely a secondary immune-complex GN (TB- or lymphoma-associated) rather than primary vasculitis. Still send ANA, dsDNA, ANCA, anti-GBM, C3/C4 — but do not let serologies delay biopsy of the mass.

  4. Quantify the renal lesion: UPCR and urine sediment microscopy now; renal biopsy only if proteinuria exceeds 1 g/day, creatinine rises, or serologies turn positive.

  5. Assess the PA stenosis hemodynamically: Echo with Doppler across the RPA, RV size/function, and estimated PA pressures. She is currently compensated (SpO2 98%, normal HR) — but document baseline for progression.

  6. Add LDH, uric acid, ACE level, and peripheral blood film — cheap discriminators: markedly elevated LDH favors lymphoma; elevated ACE supports (never proves) sarcoidosis.

Bottom line: Tissue is the issue. EBUS-TBNA of the subcarinal mass is the single highest-yield intervention — it simultaneously confirms or excludes TB, lymphoma, and sarcoidosis.

Round 3

User:

Stage 3: Advanced Diagnostic Workup & Tissue Biopsy (Timestamp: Hospital Days 3-6)
Diagnostic Investigations:
- Transthoracic Echocardiogram (TTE): Confirmed a moderate pericardial effusion without overt cardiac tamponade physiology, with right ventricular overload secondary to RPA extrinsic compression.
- EBUS-TBNA (Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration): Performed twice; retrieved non-diagnostic necrotic fluid.
- VATS Biopsy (Video-Assisted Thoracoscopic Surgery): Mediastinal window exploration with surgical core biopsy of the subcarinal mass and adjacent mediastinal lymph nodes.
Histopathology: Revealed dense necrotizing granulomatous inflammation (necrotizing granulomas).
Microbiologic & Cytologic Panels:
- Malignant Cytology: Negative for atypical or malignant cells across multiple sections.
- Mycobacterial & Fungal Studies: ZN AFB stain negative, GeneXpert MTB/RIF Ultra negative, GMS fungal stain negative, AFB & fungal MGIT cultures no growth.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* VATS core biopsy demonstrates necrotizing granulomatous inflammation.
* Microbiological tests (GeneXpert Ultra, AFB/fungal stains, and cultures) are currently negative.
* Severe RPA extrinsic compression causing RV overload; persistent dysmorphic microscopic hematuria.

Differential Diagnoses:
1. Culture-Negative / Paucibacillary Tuberculosis: 55% – Necrotizing (caseating) granulomas in Delhi NCR are overwhelmingly TB; paucibacillary necrotic samples frequently yield negative initial stains/cultures/GeneXpert.
2. Granulomatosis with Polyangiitis (GPA): 25% – Unifies necrotizing granulomatous inflammation with dysmorphic hematuria (glomerulonephritis) and pericarditis.
3. Fungal Granulomatous Infection (e.g., Histoplasmosis): 10% – Can mimic TB with necrotizing granulomas, though less common without clear exposure.
4. Necrotizing Sarcoid Granulomatosis (NSG): 10% – A rare sarcoidosis variant featuring necrosis, though usually non-caseating.

Recommended Next Steps:
1. Tissue TB-PCR / Next-Generation Sequencing (NGS): Send VATS tissue for target-enriched mycobacterial DNA testing.
2. Serologies: Serum ANCA (PR3/MPO), ANA, and complement levels.
3. Fungal Serologies & Biomarkers: Serum Galactomannan, Beta-D-Glucan, and Histoplasma antigen.
4. Renal Evaluation: Spot UPCR; consider renal biopsy if serologies are positive or kidney function declines.
5. Empiric Trial: Strongly consider empiric Anti-Tubercular Therapy (ATT) given regional endemicity and critical RPA compression.

Attending:

Attending:
Hello Attending Consultant here

Top 3 Differentials (Refined by Necrotizing Granulomas):
1. Paucibacillary Tuberculosis — necrotizing granulomas in a TB-endemic region, with negative initial stains/GeneXpert due to low bacillary load in necrotic tissue.
2. Granulomatosis with Polyangiitis (GPA) — necrotizing granulomatous inflammation, glomerular hematuria, and pericarditis; ANCA serology is now critical.
3. Fungal Granulomatous Disease — Histoplasmosis or Aspergillosis, though less likely without exposure or immunocompromise.

Critique and Augmentation of the Chief Resident’s Plan:

  1. Tissue is still the issue — but the wrong tissue was interrogated. The VATS biopsy was sent for microbiology, but histology must be re-reviewed with specific stains: ZN for AFB, GMS for fungi, and elastic tissue stains to assess for vasculitic necrosis (GPA). Necrotizing granulomas in GPA are often "geographic" with basophilic necrosis and palisading histiocytes — a pattern distinct from caseating TB granulomas.

  2. ANCA testing is now urgent, not ancillary. PR3-ANCA positivity would shift the diagnosis to GPA and mandate immediate immunosuppression, not empiric ATT. Send PR3/MPO by ELISA and immunofluorescence simultaneously.

  3. Empiric ATT is a high-stakes decision. Starting ATT without a microbiologic diagnosis risks hepatotoxicity and delays immunosuppression if GPA is the true cause. However, critical RPA stenosis with RV overload is a life-threatening mechanical complication. I recommend a 48-hour window: await ANCA result and tissue TB-PCR/NGS. If both negative and no clinical deterioration, a short course of empiric ATT under close observation is reasonable.

  4. Renal biopsy is now indicated, not optional. Persistent dysmorphic hematuria with necrotizing granulomas elsewhere demands tissue confirmation of glomerulonephritis. A crescentic GN on biopsy would strongly favor GPA and justify immunosuppression over ATT.

  5. Pericardial fluid analysis was missed. If the effusion persists, pericardiocentesis with ADA, GeneXpert, and cytology could yield a microbiologic diagnosis when the mass biopsy did not.

  6. Fungal workup must be completed before immunosuppression. Send serum galactomannan, beta-D-glucan, and Histoplasma antigen. If any are positive, steroids (for possible GPA) could be catastrophic.

  7. Multidisciplinary discussion with pulmonology, rheumatology, and cardiothoracic surgery is essential to weigh the risks of empiric therapy versus progressive vascular compression.

Expert:

Expert:
Hello, Expert Clinician here.

Best Unifying Diagnosis: Paucibacillary mediastinal tuberculosis with immune-complex glomerulonephritis. Necrotizing granulomas in Delhi NCR are TB until proven otherwise; negative GeneXpert/AFB in necrotic tissue is expected with low bacillary burden.

Top Differentials:
- GPA: Fits necrotizing granulomas, hematuria, and pericarditis — but no upper airway disease, and ANCA is pending. A positive PR3-ANCA would pivot the case entirely.
- Fungal granulomatous disease: Histoplasmosis can mimic TB; must be excluded before any immunosuppression.
- Necrotizing sarcoid granulomatosis: Rare; diagnosis of exclusion.

Key Pivot: The negative microbiology does not exclude TB — it reflects sampling of necrotic, paucibacillary tissue. The hematuria is likely secondary immune-complex GN, not primary vasculitis, unless ANCA is positive.

Most Important Next Move: Send VATS tissue for mycobacterial NGS/targeted PCR and ANCA serology simultaneously. If both negative within 48 hours and no deterioration, start empiric ATT with close monitoring of RPA stenosis and renal function.

Teaching Pearl: In TB-endemic regions, necrotizing granulomas with negative stains are still TB — the absence of proof is not proof of absence.

Round 4

User:

Stage 4: Serologic & Autoimmune Panel (Timestamp: In-hospital Serology)
With infectious causes (TB / Endemic Fungi) and malignancy largely ruled out by negative cultures and cytology, extended serologic testing was performed:
- ANCA Serology: c-ANCA (PR3-ANCA) strongly positive (ELISA titer >100 AU/mL); p-ANCA (MPO-ANCA) negative.
- Autoimmune Panel: ANA negative, Rheumatoid Factor (RF) negative, Serum ACE level normal (28 U/L).
- Infectious Serologies: HIV 1 & 2 negative, Syphilis RPR non-reactive, Brucella & Bartonella serologies negative, Fungal serology panel negative.

Resident:

Resident:
Hello, Chief Resident here.

Updated Key Findings:
* Strongly positive c-ANCA / PR3-ANCA (>100 AU/mL).
* Histopathology: Necrotizing granulomatous inflammation.
* Clinical manifestations: Subcarinal mass causing RPA compression, pericardial effusion, and dysmorphic microscopic hematuria.

Differential Diagnoses:
1. Granulomatosis with Polyangiitis (GPA): 90% – A strongly positive PR3-ANCA paired with necrotizing granulomatous inflammation and glomerular hematuria fully confirms the diagnosis.
2. False-Positive ANCA secondary to Tuberculosis: 5% – Unlikely given negative microbiological panels and high PR3-ANCA titers.
3. Microscopic Polyangiitis (MPA): 3% – Atypical given strong PR3 positivity and granulomatous features.
4. Fungal / Dual Disease state: 2% – Retained as a remote possibility.

Recommended Next Steps:
1. Urgent Immunosuppressive Therapy: Initiate high-dose IV methylprednisolone pulse therapy followed by oral prednisone, plus Rituximab or Cyclophosphamide.
2. Renal Biopsy: Confirm pauci-immune necrotizing/crescentic glomerulonephritis.
3. Pneumocystis jirovecii (PJP) Prophylaxis: Start Trimethoprim-Sulfamethoxazole.
4. Vascular Surveillance: Repeat CTPA/Echocardiogram after induction to monitor RPA compression resolution.

Attending:

Hello Attending Consultant here

Top Differentials (Finalized):
1. Granulomatosis with Polyangiitis (GPA) — 95%+ probability. Strongly positive PR3-ANCA (>100 AU/mL), necrotizing granulomas, glomerular hematuria, and pericardial effusion form a unified diagnosis.
2. Atypical Pulmonary-Renal Vasculitis overlap — 5%.

Critique & Immediate Action Plan:

  1. Diagnosis Confirmed: The high-titer PR3-ANCA resolves the diagnostic ambiguity. This is GPA presenting atypically with a mediastinal mass and RPA extrinsic compression.

  2. Immediate Induction Therapy:
    - Pulse methylprednisolone: 1 g/day IV for 3 days, followed by oral prednisone 1 mg/kg/day.
    - Rituximab: 375 mg/m² weekly x 4 doses (or 1000 mg IV on Days 1 and 15) OR IV Cyclophosphamide. Rituximab is preferred in young females to preserve fertility.

  3. Infection Prophylaxis: Trimethoprim-sulfamethoxazole (800/160 mg three times weekly) for PJP prophylaxis and secondary anti-inflammatory benefit.

  4. Renal Management: Perform urgent renal biopsy to grade crescentic involvement and baseline chronicity, guiding intensity of maintenance therapy.

  5. Vascular Monitoring: Repeat Echo/CTPA in 2–4 weeks to evaluate RPA stenosis resolution under immunosuppression. Interventional stent placement is reserved only for refractory mechanical compromise.

Expert:

Hello, Expert Clinician here.

Final Diagnosis: Granulomatosis with Polyangiitis (GPA) presenting with a mediastinal pseudotumor causing right pulmonary artery compression, pericarditis, and pauci-immune glomerulonephritis.

Key Pivot: The strongly positive PR3-ANCA (>100 AU/mL) combined with necrotizing granulomas on VATS biopsy definitively clinches GPA, completely shifting management from antimicrobial to immunosuppressive.

Management Priorities:
1. Induction: IV Methylprednisolone pulse + Rituximab (preferred over cyclophosphamide for fertility preservation).
2. Prophylaxis: TMP-SMX for PJP.
3. Monitoring: Serial echo/CTPA for RPA decompression; renal biopsy for staging.

Teaching Pearl: GPA can present as tumor-like mediastinal masses causing major vascular compression—always check PR3-ANCA before assuming infection in necrotizing granulomas.

Attending:

Hello Attending Consultant here

Top 3 Differentials (Refined at PR3-ANCA >100 AU/mL):
1. Granulomatosis with Polyangiitis (GPA) — pauci-immune necrotizing granulomatous vasculitis. Confirmed.
2. Microscopic polyangiitis with granulomatous features — rare overlap.
3. Cocaine-induced midline destructive lesion-like illness — excluded by history.

Critique of the Resident’s Plan – 6 Immediate Refinements:

  1. Renal biopsy now, not after starting immunosuppression. Confirm crescentic GN grade. If >50% crescents or rapidly rising creatinine, add plasma exchange to induction (PEXIVAS-style protocol).
  2. Rituximab dosing: Prefer 375 mg/m² weekly ×4 over two-dose regimen if weight <80 kg; ensure pre-dose CD20+ B-cell counts and screen for HBV, HCV, TB (reactivation risk).
  3. Pericardial effusion vigilance: Repeat echo at 24 hrs; a small window of tamponade can emerge with RV overload. Pre-emptive pericardiocentesis if effusion enlarges.
  4. Add PJP prophylaxis with atovaquone if TMP-SMX allergy or renal impairment, but TMP-SMX is dual-purpose (anti-PJP + mild ANCA suppression).
  5. Staging CT chest/abdomen to exclude tracheobronchial stenosis or renal masses before starting rituximab.
  6. Discuss oocyte cryopreservation if cyclophosphamide is ever used, but rituximab preserves fertility, so document counseling.

Expert:

Expert:
Hello, Expert Clinician here.

Best Unifying Diagnosis: Granulomatosis with Polyangiitis (GPA) presenting as a mediastinal pseudotumor with right pulmonary artery compression, pericardial effusion, and pauci-immune glomerulonephritis.

Top Differentials:
- Paucibacillary TB: Fits necrotizing granulomas and endemicity, but strongly positive PR3-ANCA with negative microbiology effectively excludes it.
- Fungal granulomatous disease: Excluded by negative serologies and stains.
- Necrotizing sarcoid granulomatosis: Normal ACE and positive PR3-ANCA argue against it.

Key Pivot: The strongly positive PR3-ANCA (>100 AU/mL) transforms the case from an infectious workup to a vasculitis emergency, mandating immediate immunosuppression.

Most Important Next Move: Initiate induction therapy with IV methylprednisolone pulse plus rituximab, while performing renal biopsy to stage glomerulonephritis severity.

Teaching Pearl: GPA can masquerade as a mediastinal mass causing vascular compression; always check ANCA in necrotizing granulomas before committing to empiric anti-infective therapy.

Round 5

User:

Stage 5: Final Unifying Diagnosis & Clinical Course (Timestamp: 6-Week Follow-up)
Final Unifying Diagnosis: Granulomatosis with Polyangiitis (GPA / Wegener's Granulomatosis) presenting as a subcarinal mediastinal mass with extrinsic pulmonary artery stenosis, necrotizing granulomatous lymphadenitis, pericardial effusion, and renal involvement (microscopic hematuria).
Treatment Plan: High-dose pulse IV Methylprednisolone (1g daily x 3 days) followed by induction therapy with Rituximab (anti-CD20 monoclonal antibody 375 mg/m² weekly x 4 doses) combined with Avacopan (oral C5a receptor antagonist) for steroid tapering.
Outcome: Follow-up CT Chest at 6 weeks showed dramatic regression of the subcarinal mass with complete resolution of pulmonary artery stenosis and pericardial effusion. Microscopic hematuria resolved, and the patient remains in clinical remission on Rituximab maintenance.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Confirmed diagnosis of Granulomatosis with Polyangiitis (GPA) presenting as a mediastinal pseudotumor with severe RPA stenosis, pericarditis, and glomerulonephritis.
* Complete radiological regression of the subcarinal mass, resolution of RPA stenosis, and resolution of microscopic hematuria following Rituximab, pulse steroids, and Avacopan.

Final Diagnostic Probabilities:
1. Granulomatosis with Polyangiitis (GPA): 98% – Confirmed by strongly positive PR3-ANCA, necrotizing granulomas, clinical presentation, and complete remission on anti-CD20/C5aR inhibitor therapy.
2. Infectious/Malignant Mimics (TB, Fungal, Lymphoma): 2% – Definitively excluded by negative microbiology/cytology and sustained treatment response.

Recommended Monitoring & Maintenance Steps:
1. Maintenance Therapy: Administer Rituximab (500–1000 mg IV every 6 months) for 18–24 months to maintain remission.
2. Steroid Sparing: Continue Avacopan-assisted rapid steroid taper.
3. Laboratory Surveillance: Monitor urinalysis, spot UPCR, PR3-ANCA titers, and CD19/20 B-cell depletion every 3 months.
4. Prophylaxis: Maintain TMP-SMX for PJP prophylaxis during immunosuppression.
5. Cardiopulmonary Follow-up: Repeat echocardiogram in 6 months to confirm sustained RV recovery and normal pulmonary dynamics.

Attending:

Hello Attending Consultant here

Top Differentials (Final):
1. Granulomatosis with Polyangiitis (GPA) – confirmed pseudotumor-mediated pulmonary-renal syndrome.
2. Paucibacillary TB with false-positive ANCA – excluded by anti-CD20 response.
3. Sarcoid vasculitis – normal ACE, absent non-caseating granulomas.

Critique & Refinements to the Maintenance Plan (6 points):

  1. Extended Rituximab Maintenance: Given life-threatening extrinsic pulmonary artery stenosis, consider extension to 36 months (500 mg q6mo) rather than 18–24; monitor IgG levels for secondary hypogammaglobulinemia.
  2. Avacopan Stewardship: Continue C5aR blockade to facilitate prednisone ≤5 mg/day by week 4; perform serial LFTs (hepatotoxicity) and wean avacopan after maintenance rituximab course.
  3. Biomarker Governance: Rising PR3-ANCA titers alone must not trigger pre-emptive re-treatment; anchor all decisions on clinical/radiologic relapse.
  4. PJP Duration: TMP-SMX prophylaxis should persist until CD19+ B-cells reconstitute to >1% (typically >12 months).
  5. Bone Strike Protocol: Despite early steroid taper, dual-energy X-ray absorptiometry (DEXA) now; consider bisphosphonate if T-score ≤ –2.5 post-pulse.
  6. Renal Biopsy Gap: If not performed, a protocol renal biopsy at 6 months would confirm histological remission of pauci-immune GN and inform intensity of ongoing immunosuppression.

Expert:

Expert:
Hello, Expert Clinician here.

Best Unifying Diagnosis: Granulomatosis with Polyangiitis (GPA) presenting as a mediastinal pseudotumor with right pulmonary artery compression, pericardial effusion, and pauci-immune glomerulonephritis.

Top Differentials:
- Paucibacillary TB: Fits necrotizing granulomas and endemicity, but strongly positive PR3-ANCA and complete response to rituximab exclude it.
- Fungal granulomatous disease: Excluded by negative serologies and stains.
- Necrotizing sarcoid granulomatosis: Normal ACE and positive PR3-ANCA argue against it.

Key Pivot: The strongly positive PR3-ANCA (>100 AU/mL) transformed the case from an infectious workup to a vasculitis emergency, mandating immediate immunosuppression.

Most Important Next Move: Continue rituximab maintenance with avacopan-assisted steroid taper, while monitoring for relapse via clinical assessment, urinalysis, and PR3-ANCA titers.

Teaching Pearl: GPA can masquerade as a mediastinal mass causing vascular compression; always check ANCA in necrotizing granulomas before committing to empiric anti-infective therapy.

Top 15 Takeaways for Clinicians

  1. Mediastinal Pseudotumor as an Atypical Presentation of GPA: Granulomatosis with Polyangiitis (GPA) can present as a solitary mass-like subcarinal lymphadenopathy causing critical extrinsic compression of the main pulmonary artery, mimicking lymphoma or tuberculosis.
  2. Microscopic Hematuria as a Diagnostic Red Flag: Persistent microscopic hematuria in a patient presenting with dyspnea or mediastinal mass is a key pivot elevating the differential from isolated PE/mass to a pulmonary-renal vasculitic syndrome.
  3. Mandatory ANCA Testing in Necrotizing Granulomatous Inflammation: In any biopsy showing necrotizing granulomas, PR3-ANCA / c-ANCA testing is imperative before committing the patient to empiric anti-tubercular therapy or toxic immunosuppression.
  4. Necrotizing Granulomas vs. Caseating Granulomas: Geographic basophilic necrosis with palisading histiocytes and leucocytoclastic vasculitis favors GPA, whereas classic caseating granulomas favor tuberculosis.
  5. GeneXpert MTB Ultra for Mycobacterial Exclusion: Rapid NAAT (GeneXpert Ultra) and MGIT liquid cultures are essential in TB-endemic regions to exclude paucibacillary TB before initiating high-dose immunosuppression.
  6. Rituximab vs. Cyclophosphamide for Remission Induction: Anti-CD20 therapy (Rituximab 375 mg/m² weekly x 4) is preferred over cyclophosphamide for organ- or life-threatening GPA, particularly in young patients to preserve fertility.
  7. Avacopan as a C5a Receptor Antagonist for Steroid Sparing: Adding Avacopan (oral selective C5aR inhibitor) to Rituximab accelerates glucocorticoid tapering, reducing steroid-induced morbidity while maintaining remission.
  8. Echocardiographic Surveillance for Extrinsic Vascular Stenosis: Serial Doppler echocardiography is crucial to monitor right ventricular strain and document hemodynamic decompression of the right pulmonary artery.
  9. Role of Protocol Renal Biopsy: In patients with pauci-immune glomerulonephritis, early renal biopsy quantifies crescentic activity and guides the intensity and duration of maintenance immunosuppression.
  10. Pneumocystis jirovecii Pneumonia (PJP) Prophylaxis: Daily single-strength Trimethoprim-Sulfamethoxazole (Bactrim) is mandatory during Rituximab-induced B-cell depletion for PJP prophylaxis and secondary ANCA suppression.
  11. Monitoring B-Cell Depletion and PR3-ANCA Titers: Serial quantification of CD19/CD20 B-cells and PR3-ANCA titers helps assess treatment compliance, though clinical relapse should guide re-treatment over rising titers alone.
  12. Screening for Viral Reactivation Before Biologic Induction: Pre-induction screening for Hepatitis B, Hepatitis C, and latent Tuberculosis is mandatory before initiating high-dose anti-CD20 therapy.
  13. Risk of Secondary Hypogammaglobulinemia: Long-term maintenance Rituximab (500–1000 mg every 6 months for 24–36 months) requires periodic serum IgG monitoring to detect secondary immunodeficiency.
  14. Management of Co-existing Pericardial Effusions: Pericarditis and pericardial effusions in GPA represent systemic serositis; pericardiocentesis is indicated for hemodynamic compromise or diagnostic clarification.
  15. Multidisciplinary Team Coordination: Complex GPA presentations with major vascular compression require close coordination between pulmonology, rheumatology, nephrology, and cardiothoracic surgery.